Advertisement

Topics

Novartis International AG: Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001)

02:41 EDT 14 Jun 2019 | FinanzNachrichten

Novartis International AG / Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound ...

Original Article: Novartis International AG: Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001)

NEXT ARTICLE

More From BioPortfolio on "Novartis International AG: Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...